Navigation Links
Transdel Enrolls First Patient for Ketotransdel(TM) Phase 3 Clinical Trial
Date:9/22/2008

d in Ketotransdel(TM), in other products. Accordingly, the Company is investigating other drug candidates and treatments for transdermal delivery using the Transdel(TM) platform technology for products in pain management and other therapeutic areas. Furthermore, the Company is exploring potential partnerships with U.S. and foreign based companies that have sales and marketing infrastructures to support Ketotransdel(TM) in the event that the product is approved and commercialized. The Company is also looking to out-license its Transdel(TM) drug delivery technology for the development and commercialization of additional innovative drug products.

About Transdel Pharmaceuticals, Inc.

Transdel Pharmaceuticals, Inc. (OTC Bulletin Board: TDLP) is a specialty pharmaceutical company developing non-invasive, topically-delivered medications. The Company's innovative patented proprietary Transdel(TM) cream formulation technology is designed to facilitate the effective penetration of drugs through the tough skin barrier to reach the target underlying tissues. In the case of Ketotransdel(TM), the Transdel(TM) cream allows the active ingredient ketoprofen to reach the target soft tissue and exert its well-known anti-inflammatory and analgesic effects. The Company is also investigating other drug candidates and treatments for transdermal delivery using the patented Transdel(TM) platform technology for products in pain management and other therapeutic areas. For more information, please visit http://www.transdelpharma.com .

Safe Harbor Statement

Statements made in this release that are not historical in nature constitute forward-looking statements within the meaning of the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Forward- looking statements can be identified by the use of words such as "expects," plans" "will," "may," "anticipates," believes," "should," intend
'/>"/>

SOURCE Transdel Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Transdel Pharmaceuticals Advances Lead Topical Pain Drug into Phase 3 Program
2. Transdel Initiates Ketotransdel(TM) Phase 3 Clinical Program for Pain
3. Spectranetics Enrolls First Patient in PATENT Trial for the Treatment of Instent Restenosis
4. VIA Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial to Measure Impact of VIA-2291 to Reduce Vascular Inflammation
5. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
6. Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors
7. Novagali Pharma Successfully Enrolls First Patient in U.S. Phase I Clinical Study with CORTIJECT(R) for Diabetic Macular Edema
8. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
9. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
10. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
11. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... -- TechniScan, Inc. (OTC Bulletin Board: ... company engaged in the development and commercialization of ... that Joe Pepper, PhD, has been appointed to ... Chairman Ken Hungerford commented, "Joe has extensive experience ... GE OEC Medical and U-Systems, both of whom ...
(Date:12/16/2009)... EVANSTON, Ill., Dec. 16 Naurex Inc., ... for depression and other CNS disorders based on ... that it has initiated a Phase I clinical ... successfully dosed the first subjects in the study. ... (GFPA) selective modulator of the NMDA receptor, is ...
(Date:12/16/2009)... PALO ALTO, Calif., Dec. 16 The ... Intradigm Corporation are delighted to announce the merger ... in the field of RNAi (RNA interference). ... will have multiple RNAi discovery, development and delivery ... and a broad portfolio of intellectual property. ...
Breaking Medicine Technology:In Preparation for Commercialization of SVARA(TM), TechniScan Appoints Joe Pepper, PhD to Board of Directors 2In Preparation for Commercialization of SVARA(TM), TechniScan Appoints Joe Pepper, PhD to Board of Directors 3Naurex Inc. Initiates Phase I Clinical Trial of its Novel Mechanism NMDA Modulator GLYX-13 in Treatment-Resistant Depression 2Naurex Inc. Initiates Phase I Clinical Trial of its Novel Mechanism NMDA Modulator GLYX-13 in Treatment-Resistant Depression 3Silence Therapeutics to Merge with Intradigm Corp to Create Leading RNAi Therapeutics Company 2Silence Therapeutics to Merge with Intradigm Corp to Create Leading RNAi Therapeutics Company 3Silence Therapeutics to Merge with Intradigm Corp to Create Leading RNAi Therapeutics Company 4Silence Therapeutics to Merge with Intradigm Corp to Create Leading RNAi Therapeutics Company 5Silence Therapeutics to Merge with Intradigm Corp to Create Leading RNAi Therapeutics Company 6WuXi PharmaTech Appoints Wei Min Chang as Vice President of Operations and General Manager of SynTheAll Manufacturing Facility Eric Gu as Vice Presid 12715 1WuXi PharmaTech Appoints Wei Min Chang as Vice President of Operations and General Manager of SynTheAll Manufacturing Facility Eric Gu as Vice Presid 12715 2Transplant drug stimulates immune memory 49553 1Transplant drug stimulates immune memory 49553 2United Nations Secretary General Ban Ki moon to Keynote Rotary Internationals 100th Annual Meeting 49552 1United Nations Secretary General Ban Ki moon to Keynote Rotary Internationals 100th Annual Meeting 49552 2United Nations Secretary General Ban Ki moon to Keynote Rotary Internationals 100th Annual Meeting 49552 3
... Anthera Pharmaceuticals,Inc. today announced it has ... Patheon Inc. The agreements provide for the,large-scale ... expected,to be necessary in preparation for Anthera,s ... Application submission to the Food and Drug,Administration. ...
... Mayo clinic in key role in treatment discovery, ... New York,based company Cytopia Limited (ASX: CYT) announced ... demonstrated potent activity in cells,isolated from patients with ... of diseases where there is over-production of,particular cells ...
Other Medicine Technology:Anthera Enters Into Manufacturing Agreements for Varespladib in Preparation for Pivotal Phase III Trials 2JAK2 Inhibitor Shows Potent Activity in Cells From MPD Patients 2
(Date:12/17/2009)... Cost/Risk Analysis reports, activity measures and outcomes reporting to monitor ... reduced claim costs and positive return on investment over the ... ... Jacksonville, FL (PRWEB) December 17, 2009 -- HealthScreen ... clinical/claims based cost risk analysis along with personalized nurse care, ...
(Date:12/16/2009)... 17 If proposed health care legislation ... the employer-based insurance system. Approximately 18.4 million Californians ... 65 rely upon employer-based insurance for their health ... versions of reform legislation entail specific requirements for ... employees work for firms that currently comply with ...
(Date:12/16/2009)... of Children with Autism and Other Special Needs, ... Levi Join Ben Stiller to Ring in the Holiday ... At its 13th annual Teddy Bear Ball, The Help ... CEO Brian Goldner received the ... philanthropic leadership and commitment to children,s causes; parent ...
(Date:12/16/2009)... Immucor, Inc. (Nasdaq: BLUD ), a global leader ... industry, today announced that Paul D. Mintz, M.D. has ... director, effective January 1, 2010. ,, Dr. Mintz ... for more than 30 years. He is a tenured ... Virginia School of Medicine. He also serves as director ...
(Date:12/16/2009)... --The most widely used human embryonic stem cell lines ... questions that must be addressed to ensure that all ... to a University of Michigan research team. ,, In ... team analyzed 47 embryonic stem cell lines, including most ... The scientists determined the genetic ancestry of each line ...
Breaking Medicine News(10 mins):Health News:Baptist Health System Selects HealthScreen Disease Management for Employee Health Management Services 2Health News:How National Health Reform Proposals Would Affect Employer-Based Plans in California 2Health News:How National Health Reform Proposals Would Affect Employer-Based Plans in California 3Health News:The Help Group Honors Brian Goldner, Mary Urquhart and Max Mayer at its Teddy Bear Ball Featuring Ben Stiller and Celebrity Guests 2Health News:The Help Group Honors Brian Goldner, Mary Urquhart and Max Mayer at its Teddy Bear Ball Featuring Ben Stiller and Celebrity Guests 3Health News:The Help Group Honors Brian Goldner, Mary Urquhart and Max Mayer at its Teddy Bear Ball Featuring Ben Stiller and Celebrity Guests 4Health News:The Help Group Honors Brian Goldner, Mary Urquhart and Max Mayer at its Teddy Bear Ball Featuring Ben Stiller and Celebrity Guests 5Health News:Immucor Appoints New Board Director 2Health News:U-M Study Reveals Surprising Lack of Genetic Diversity in the Most Widely Used Human Embryonic Stem Cell Lines 2Health News:U-M Study Reveals Surprising Lack of Genetic Diversity in the Most Widely Used Human Embryonic Stem Cell Lines 3Health News:U-M Study Reveals Surprising Lack of Genetic Diversity in the Most Widely Used Human Embryonic Stem Cell Lines 4Health News:U-M Study Reveals Surprising Lack of Genetic Diversity in the Most Widely Used Human Embryonic Stem Cell Lines 5
... issue of the Cochrane Library journal concludes //that the three ... and Viagra appear to be safe and effective for men ... medications called phosphodiesterase type 5 (PDE-5) inhibitors. ,Diabetes ... have estimated that the diabetic men are about three times ...
... ‘Careless’ is perhaps too mild a word to describe the women ... yet throw caution to the winds, in life and death matters. ... of four women, do not consider themselves to be at risk ... got together for a research which showed that 70% of women ...
... found that the Schering-Plough fungus-fighter drug - Noxafil, //which ... in protecting patients with crippled immune systems, according to ... of their study were published in the New England ... fungal infections, Noxafil, known generically as posaconazole, also seems ...
... all set to tighten the screws on smoking and ... hearing starting on Jan 23, is scheduled in which ... before the committee. ,Under the original act ... sports and other popular events by tobacco companies is ...
... as though reprieve from prostate cancer is as close as ... estimated 32,000 men who are diagnosed with the disease// annually. ... to the disease every year. ,A novel study ... in the management of prostate cancer. Scientists have found that, ...
... about the usage of cholesterol lowering drugs has revealed ... a means to prevent heart disease; Researchers warn// that ... life-threatening health risks for those suffering vascular disease. ... reducing the risk of heart attack and cardiovascular problems ...
Other Medicine News:Health News:ED Drugs - Safe and Effective for Diabetic Men 2Health News:How Veggie Pros, Tomato and Broccoli, Con Prostate Cancer 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: